Tommy DiRaimondo, Ph.D. joined the Accelerator in 2013 and currently serves as the Director of Research at Janux Therapeutics, an Avalon portfolio company. Previously, Tommy was the co-founder of Sitari Pharma that spawned from his predoctoral work at Stanford University. Tommy was a key leader in the Sitari Pharma drug discovery and development program whose successful culmination was the acquisition by GlaxoSmithKline. Tommy studied as a predoctoral scholar at Stanford University where he received his Ph.D. in the department of Chemical Engineering. Tommy received a Master’s in Engineering and Bachelor’s in Science and Engineering from the University of Michigan Ann Arbor in the departments of Chemical Engineering and Pharmaceutical Engineering, respectively.